PROCTER & GAMBLE HEALTH | VIVIMED LABS | PROCTER & GAMBLE HEALTH/ VIVIMED LABS |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 35.0 | -0.1 | - | View Chart |
P/BV | x | 10.7 | 1.0 | 1,034.9% | View Chart |
Dividend Yield | % | 2.0 | 0.0 | - |
PROCTER & GAMBLE HEALTH VIVIMED LABS |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
PROCTER & GAMBLE HEALTH Jun-23 |
VIVIMED LABS Mar-23 |
PROCTER & GAMBLE HEALTH/ VIVIMED LABS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 5,366 | 17 | 30,890.0% | |
Low | Rs | 3,883 | 7 | 58,215.9% | |
Sales per share (Unadj.) | Rs | 740.7 | 22.6 | 3,282.5% | |
Earnings per share (Unadj.) | Rs | 138.2 | -39.6 | -348.9% | |
Cash flow per share (Unadj.) | Rs | 155.2 | -26.5 | -584.4% | |
Dividends per share (Unadj.) | Rs | 95.00 | 0 | - | |
Avg Dividend yield | % | 2.1 | 0 | - | |
Book value per share (Unadj.) | Rs | 447.6 | 4.8 | 9,414.1% | |
Shares outstanding (eoy) | m | 16.60 | 82.91 | 20.0% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 6.2 | 0.5 | 1,171.9% | |
Avg P/E ratio | x | 33.5 | -0.3 | -11,027.1% | |
P/CF ratio (eoy) | x | 29.8 | -0.5 | -6,582.4% | |
Price / Book Value ratio | x | 10.3 | 2.5 | 408.6% | |
Dividend payout | % | 68.7 | 0 | - | |
Avg Mkt Cap | Rs m | 76,761 | 997 | 7,702.1% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 2,062 | 327 | 631.1% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 12,296 | 1,871 | 657.2% | |
Other income | Rs m | 184 | 10 | 1,899.8% | |
Total revenues | Rs m | 12,480 | 1,881 | 663.6% | |
Gross profit | Rs m | 3,247 | -1,870 | -173.6% | |
Depreciation | Rs m | 281 | 1,084 | 25.9% | |
Interest | Rs m | 8 | 362 | 2.1% | |
Profit before tax | Rs m | 3,142 | -3,307 | -95.0% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 847 | -21 | -4,002.4% | |
Profit after tax | Rs m | 2,295 | -3,285 | -69.8% | |
Gross profit margin | % | 26.4 | -99.9 | -26.4% | |
Effective tax rate | % | 27.0 | 0.6 | 4,211.9% | |
Net profit margin | % | 18.7 | -175.6 | -10.6% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,713 | 3,323 | 352.5% | |
Current liabilities | Rs m | 6,791 | 4,243 | 160.0% | |
Net working cap to sales | % | 40.0 | -49.2 | -81.4% | |
Current ratio | x | 1.7 | 0.8 | 220.2% | |
Inventory Days | Days | 263 | 389 | 67.5% | |
Debtors Days | Days | 343 | 150 | 229.2% | |
Net fixed assets | Rs m | 10,617 | 6,561 | 161.8% | |
Share capital | Rs m | 166 | 166 | 100.1% | |
"Free" reserves | Rs m | 7,265 | 228 | 3,180.7% | |
Net worth | Rs m | 7,431 | 394 | 1,884.9% | |
Long term debt | Rs m | 0 | 623 | 0.0% | |
Total assets | Rs m | 22,330 | 9,883 | 225.9% | |
Interest coverage | x | 409.1 | -8.1 | -5,033.1% | |
Debt to equity ratio | x | 0 | 1.6 | 0.0% | |
Sales to assets ratio | x | 0.6 | 0.2 | 290.9% | |
Return on assets | % | 10.3 | -29.6 | -34.9% | |
Return on equity | % | 30.9 | -833.4 | -3.7% | |
Return on capital | % | 42.4 | -289.4 | -14.6% | |
Exports to sales | % | 0 | 0.9 | 0.0% | |
Imports to sales | % | 13.1 | 0 | - | |
Exports (fob) | Rs m | NA | 17 | 0.0% | |
Imports (cif) | Rs m | 1,605 | NA | - | |
Fx inflow | Rs m | 1,465 | 17 | 8,853.2% | |
Fx outflow | Rs m | 1,605 | 0 | - | |
Net fx | Rs m | -140 | 17 | -847.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,360 | 353 | 668.1% | |
From Investments | Rs m | -215 | -50 | 432.8% | |
From Financial Activity | Rs m | -985 | -338 | 291.5% | |
Net Cashflow | Rs m | 1,160 | -34 | -3,390.7% |
Indian Promoters | % | 0.0 | 20.9 | - | |
Foreign collaborators | % | 51.8 | 0.0 | - | |
Indian inst/Mut Fund | % | 20.0 | 1.8 | 1,134.7% | |
FIIs | % | 6.2 | 1.6 | 380.5% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 48.2 | 79.1 | 60.9% | |
Shareholders | 56,778 | 49,016 | 115.8% | ||
Pledged promoter(s) holding | % | 0.0 | 37.1 | - |
Compare PROCTER & GAMBLE HEALTH With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB MANKIND PHARMA
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | Procter & Gamble Health | VIVIMED LABS | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | 1.06% | -3.92% | 0.34% |
1-Month | -0.15% | -10.42% | 0.25% |
1-Year | 2.57% | -52.88% | 54.31% |
3-Year CAGR | -9.17% | -22.63% | 15.04% |
5-Year CAGR | 5.13% | -38.72% | 19.87% |
* Compound Annual Growth Rate
Here are more details on the Procter & Gamble Health share price and the VIVIMED LABS share price.
Moving on to shareholding structures...
The promoters of Procter & Gamble Health hold a 51.8% stake in the company. In case of VIVIMED LABS the stake stands at 20.9%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of Procter & Gamble Health and the shareholding pattern of VIVIMED LABS.
Finally, a word on dividends...
In the most recent financial year, Procter & Gamble Health paid a dividend of Rs 95.0 per share. This amounted to a Dividend Payout ratio of 68.7%.
VIVIMED LABS paid Rs 0.0, and its dividend payout ratio stood at -0.0%.
You may visit here to review the dividend history of Procter & Gamble Health, and the dividend history of VIVIMED LABS.
For a sector overview, read our pharmaceuticals sector report.
After opening the day on positive note, Indian share markets continued the momentum as the session progressed and ended on firm footing.